Enovis Corporation Q2 FY2025 earnings call

Damian McDonald, new CEO, emphasized near-term priorities: commercial execution, innovation, operational excellence, and financial discipline. In Recon, growth was driven by new product launches like Nebula hip and ARG shoulder, but Arvis launch was delayed by 6 months. P&R saw 3% organic growth with margin improvement. Focus on enabling technologies like Arvis and new product launches in bracing were highlighted.

In the second quarter, Recon delivered organic growth of 8%, with Global Extremities showing high single-digit growth and Global Hips and Knees at mid-single-digit growth. P&R had 3% organic growth. Recon's revenue contribution is significant due to its growth, while P&R's performance is stable in line with strategic plans.

Ben Berry raised revenue guidance to $2.245 billion to $2.275 billion, organic growth guidance to 6.25% to 6.75%, adjusted EBITDA range to $392 million to $402 million, and adjusted earnings per share range to $3.05 to $3.20. Expect positive free cash flow in 2025 and focus on debt reduction.

Tariff uncertainties, integration challenges from recent acquisitions, and the delay in Arvis launch which extended the commercial timeline are key risks.

Q: Danielle Antalffy asked about shoulder market strategy and P&R turnaround.

A: Damian McDonald talked about layered approach to competitiveness and Phillip Benjamin Berry noted P&R's consistent performance.

Q: Dane Reinhardt asked about end markets and R&D allocation.

A: Phillip Benjamin Berry discussed end market evolution and Damian McDonald explained R&D as a shift in resource allocation rather than expansion